Literature DB >> 10318863

Interactions of CD45-associated protein with the antigen receptor signaling machinery in T-lymphocytes.

A Veillette1, D Soussou, S Latour, D Davidson, F G Gervais.   

Abstract

CD45 is a transmembrane protein tyrosine phosphatase playing an essential role during T-cell activation. This function relates to the ability of CD45 to regulate p56(lck), a cytoplasmic protein tyrosine kinase necessary for T-cell antigen receptor (TCR) signaling. Previous studies have demonstrated that CD45 is constitutively associated in T-lymphocytes with a transmembrane molecule termed CD45-AP (or lymphocyte phosphatase-associated phosphoprotein). Even though the exact role of this polypeptide is unclear, recent analyses of mice lacking CD45-AP have indicated that its expression is also required for optimal T-cell activation. Herein, we wished to understand better the function of CD45-AP. The results of our studies showed that in T-cells, CD45-AP is part of a multimolecular complex that includes not only CD45, but also TCR, the CD4 and CD8 coreceptors, and p56(lck). The association of CD45-AP with TCR, CD4, and CD8 seemed to occur via the shared ability of these molecules to bind CD45. However, binding of CD45-AP to p56(lck) could take place in the absence of other lymphoid-specific components, suggesting that it can be direct. Structure-function analyses demonstrated that such an interaction was mediated by an acidic segment in the cytoplasmic region of CD45-AP and by the kinase domain of p56(lck). Interestingly, the ability of CD45-AP to interact with Lck in the absence of other lymphoid-specific molecules was proportional to the degree of catalytic activation of p56(lck). Together, these findings suggest that CD45-AP is an adaptor molecule involved in orchestrating interactions among components of the antigen receptor signaling machinery. Moreover, they raise the possibility that one of the functions of CD45-AP is to recognize activated Lck molecules and bring them into the vicinity of CD45.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10318863     DOI: 10.1074/jbc.274.20.14392

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  A regulatory polymorphism at position -309 in PTPRCAP is associated with susceptibility to diffuse-type gastric cancer and gene expression.

Authors:  Hyoungseok Ju; Byungho Lim; Minjin Kim; Yong Sung Kim; Woo Ho Kim; Chunhwa Ihm; Seung-Moo Noh; Dong Soo Han; Hang-Jong Yu; Bo Youl Choi; Changwon Kang
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

2.  CD45-associated protein promotes the response of primary CD4 T cells to low-potency T-cell receptor (TCR) stimulation and facilitates CD45 association with CD3/TCR and lck.

Authors:  David Leitenberg; Rustom Falahati; Dan Dan Lu; Akiko Takeda
Journal:  Immunology       Date:  2007-04-12       Impact factor: 7.397

3.  Distinct Transcriptomic Features are Associated with Transitional and Mature B-Cell Populations in the Mouse Spleen.

Authors:  Eden Kleiman; Daria Salyakina; Magali De Heusch; Kristen L Hoek; Joan M Llanes; Iris Castro; Jacqueline A Wright; Emily S Clark; Derek M Dykxhoorn; Enrico Capobianco; Akiko Takeda; Jean-Christophe Renauld; Wasif N Khan
Journal:  Front Immunol       Date:  2015-02-11       Impact factor: 7.561

4.  Lymphocyte phosphatase-associated phosphoprotein proteoforms analyzed using monoclonal antibodies.

Authors:  Alexander Filatov; Natalia Kruglova; Tatiana Meshkova; Dmitriy Mazurov
Journal:  Clin Transl Immunology       Date:  2015-10-09

5.  Constitutive and activation-dependent phosphorylation of lymphocyte phosphatase-associated phosphoprotein (LPAP).

Authors:  Natalia A Kruglova; Tatiana D Meshkova; Arthur T Kopylov; Dmitriy V Mazurov; Alexander V Filatov
Journal:  PLoS One       Date:  2017-08-21       Impact factor: 3.240

6.  C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease.

Authors:  Johannes Landskron; Sigrid M Kraggerud; Elisabeth Wik; Anne Dørum; Merete Bjørnslett; Espen Melum; Øystein Helland; Line Bjørge; Ragnhild A Lothe; Helga B Salvesen; Kjetil Taskén
Journal:  PLoS One       Date:  2017-07-31       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.